Is Mirum Pharmaceuticals (MIRM) Cheap As Leadership Changes Raise New Valuation Questions?

Mirum Pharmaceuticals (MIRM) has drawn fresh attention after appointing hepatologist Rob Myers, M.D., as Chief Medical Officer, replacing Joanne Quan, M.D., and lining up investor-facing presentations at two New York healthcare conferences.

Mirum Pharmaceuticals’ recent leadership reshuffle and conference schedule come after a period where the share price has eased, with the 30 day share price return down 2.4% and the 90 day move down 3.3%, yet the year to date share price return of 25.8% and a five year total shareholder return above 4x indicate longer term momentum that investors are still weighing against recent changes in the company’s story.

Compare Mirum Pharmaceuticals with a hand picked pool of rare disease and specialty pharma stocks by scanning the 15 high quality undiscovered gems that are still flying under most investors’ radar.

Mirum Pharmaceuticals now trades at a steep discount to both analyst targets and estimated fair value after a soft few months in the share price. Is that gap a genuine opportunity, or a warning that the market is pricing in something real?

Most Popular Narrative: 29% Undervalued

Mirum Pharmaceuticals last closed at $98.22, compared with a widely followed fair value estimate of $138.21, so the narrative centers on whether the current discount reflects temporary uncertainty or something more structural in the rare disease story.

The expanding addressable patient population for Mirum’s therapies, especially with the increased recognition and diagnosis of later-onset PFIC through broader use of genetic testing and heightened disease awareness, is driving higher-than-expected patient volumes. This growing patient base is expected to directly contribute to sustained top-line revenue growth.

See why 12 investors see Mirum Pharmaceuticals as 29% undervalued.

Result: Fair Value of $138.21 (UNDERVALUED)

Still, the Mirum Pharmaceuticals story can change quickly if Livmarli faces tougher competition or if key trials, such as volixibat in PSC, encounter regulatory setbacks.

Find out about the key risks to this Mirum Pharmaceuticals narrative.

Next Steps

Mixed signals around Mirum Pharmaceuticals can make the story feel messy, so move quickly, review both sides of the data, then weigh the 3 key rewards and 2 important warning signs.

Looking for more Mirum Pharmaceuticals sized ideas?

If you stop with Mirum Pharmaceuticals, you risk missing other opportunities that fit your style, your risk tolerance, and your return goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com